BA
AZN icon

Boston Advisors’s AstraZeneca AZN Stock Holding History

Boston Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,322
Closed -$466K – 658
2015
Q3 		$466K Hold
7,322
– – 0.02% 540
2015
Q2 		$466K Buy
7,322
+490
+7% +$33.5K 0.02% 489
2015
Q1 		$468K Sell
6,832
-123
-2% -$8.55K 0.02% 483
2014
Q4 		$489K Hold
6,955
– – 0.02% 343
2014
Q3 		$497K Buy
6,955
+123
+2% +$9K 0.02% 342
2014
Q2 		$508K Sell
6,832
-100
-1% -$7.23K 0.02% 349
2014
Q1 		$450K Sell
6,932
-1,518
-18% -$98K 0.02% 358
2013
Q4 		$502K Buy
8,450
+2,575
+44% +$140K 0.02% 344
2013
Q3 		$305K Sell
5,875
-897
-13% -$45.1K 0.02% 410
2013
Q2 		$320K Buy
+6,772
New +$345K 0.02% 385

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Boston Advisors's AZN Position: Q4 2015 in Review

Boston Advisors sold out of AstraZeneca (AZN) in Q4 2015, closing a stake of 7,322 shares — an estimated $466K sold.

Boston Advisors first reported a position in AZN in Q2 2013 and held it in 10 quarters. The position peaked at $508K in Q2 2014. 390 funds tracked by Wall St. Rank hold AZN as of Q4 2015.

  • Boston Advisors reported no remaining AstraZeneca position as of Q4 2015 after selling out during the quarter.
  • Boston Advisors sold 7,322 AstraZeneca shares in Q4 2015, an estimated $466K.
  • Boston Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 10 quarters.
  • Boston Advisors's AstraZeneca position peaked at $508K in Q2 2014.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2015.

Based on Boston Advisors's 13F filing for Q4 2015, filed 20 Jan 2016.